医药行业周报：Vyvgart Hytrulo获批新适应症，用于治疗CIDP

Investment Ratings - The report does not provide specific ratings for the chemical pharmaceuticals and traditional Chinese medicine industries, while the biopharmaceutical sector is rated as neutral [1][6]. Core Insights - The pharmaceutical sector experienced a decline of -2.24% on June 24, 2024, underperforming the CSI 300 index by 1.70 percentage points, ranking 14th among 31 sub-industries in the Shenwan classification [3]. - Among sub-industries, medical equipment (-0.85%), medical research outsourcing (-1.70%), and blood products (-2.01%) performed relatively well, while offline pharmacies (-3.73%), in vitro diagnostics (-3.35%), and other biological products (-3.29%) lagged behind [3]. - Notable stock performances included Tai'an Retreat (+8.70%), Haofan Bio (+5.52%), and Garden Bio (+3.61%) on the gainers' list, while Eddie Pharmaceuticals (-14.19%), Tonghe Pharmaceuticals (-9.99%), and Nanhua Bio (-9.98%) were among the biggest losers [3]. Industry News - Argenx announced that the FDA has approved Vyvgart Hytrulo for expanded indications to treat adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP), marking it as the first new therapy with a clear mechanism of action for CIDP [4]. - Han Yu Pharmaceutical received a notification from the FDA regarding the tentative approval of its liraglutide injection abbreviated new drug application (ANDA), positively impacting its expansion into the U.S. market [4]. - Yahui Pharmaceutical's APL-1202 for treating free-living amoeba infections received clinical trial approval from the National Medical Products Administration [4]. - Fuan Pharmaceutical's subsidiary BoSheng received approval for indobufen tablets, indicated for thromboembolic conditions [4]. - Staidson, a subsidiary of Shutaishen, received a "Study May Proceed Letter" from the FDA to conduct clinical trials for SBT1901 injection targeting advanced or metastatic solid tumors [4]. Sub-industry Ratings - The report indicates a neutral outlook for the biopharmaceutical sector, expecting overall returns to be within -5% to 5% relative to the CSI 300 index over the next six months [6].